Eyenovia, Inc. (EYEN)
| Market Cap | 163.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.80M |
| Shares Out | 22.21M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $6.56 |
| Previous Close | $6.57 |
| Change ($) | -0.01 |
| Change (%) | -0.15% |
| Day's Open | 6.45 |
| Day's Range | 6.33 - 6.89 |
| Day's Volume | 118,350 |
| 52-Week Range | 1.77 - 6.96 |
Today, we revisit a promising small ocular biopharma concern called Eyenovia for the first time in almost 18 months. The company continues to advance its pipeline and recently submitted a mark...
NEW YORK--(BUSINESS WIRE)-- #FDA--Eyenovia has submitted an NDA to the FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the Optejet dispenser.
NEW YORK--(BUSINESS WIRE)-- #Eyenovia--Eyenovia has enrolled its first patients in the Phase 3 VISION-1 Study of MicroLine for the improvement in near vision in patients with presbyopia.
NEW YORK--(BUSINESS WIRE)-- #Eyenovia--Eyenovia obtains FDA acceptance of its IND application for MicroLine, a therapy designed for improvement in near vision in patients with presbyopia.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript
Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.
Company reaffirms near term milestones for the Mydcombi™ (MicroStat) NDA and the MicroLine presbyopia program Phase III results
One year ago, I recommended Eyenovia's stock based on the company's effort in addressing several ophthalmic needs. Since that time, the stock has stagnated yet two collaborations have been ann...
LAVAL, QC and NEW YORK, Oct. 12, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, its leading global eye health business, and Eyenovia, Inc.,...
NEW YORK--(BUSINESS WIRE)-- #AAOPT--Drs. Siddarth Rathi, April Jasper to present latest analyses and updates from Eyenovia's clinical studies at the American Academy of Optometry 2020
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...
NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...
NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2020 Results - Earnings Call Transcript
Eyenovia (EYEN) is in the news Tuesday after an exclusive deal with Arctic Vision for two of its treatments sent EYEN stock soaring higher. The post Eyenovia News: Why EYEN Stock Is Skyrocketi...
Eyenovia Inc. (NASDAQ: EYEN) shares soared on Tuesday after the company announced an exclusive license agreement with Artic Vision to develop and commercialize its MicroPine for the treatment ...
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its ...
NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2020 Results - Earnings Call Transcript
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its ...
As of late, it has definitely been a great time to be an investor Eyenovia
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2019 Results - Earnings Call Transcript
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its ...
NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing it...
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
As of late, it has definitely been a great time to be an investor Eyenovia, Inc. (EYEN).
Eyenovia, Inc. (EYEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2019 Results - Earnings Call Transcript
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
Defers development activities of MicroProst and MicroTears
Eyenovia is a specialty ophthalmic company targeting several ophthalmic needs, including progressive myopia and presbyopia.
NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing it...
Today, we take an in-depth look at a microcap 'Busted IPO' named Eyenovia.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2019 - Earnings Call Transcript
CEO of Eyenovia Inc (30-Year Financial, Insider Trades) Tsontcho Ianchulev (insider trades) bought 233,813 shares of EYEN on 07/11/2019 at an average price of $2.78 a share.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2019 Results - Earnings Call Transcript
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2018 Results - Earnings Call Transcript
About EYEN
Eyenovia, a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. The company, throug... [Read more...]
| Industry Biotechnology | IPO Date Jan 25, 2018 |
| CEO Dr. Tsontcho Ianchulev M.P.H., M.D., MPH | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol EYEN |
Analyst Forecasts
According to 3 analysts, the average rating for Eyenovia stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 82.93% from the latest price.